Despite recent revenue growth, the company's high P/S ratio compared to the industry could disappoint shareholders. Slower revenue growth and an elevated P/S suggest a risk of share price decline. Continuation of medium-term revenue trends could put investments at risk and potential investors may pay an excessive premium.
Jiangsu Aidea Pharmaceutical Stock Forum
No comment yet